Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirepemat for reduction of falls in Parkinson's disease
NL-OMON56278Phase 2Completed
- Sponsor
- IRLAB
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing pirepemat with placebo (2 arms). Primary endpoint: Change in falls frequency. Started Apr 2024; status: completed.
02
Drugs
Pirepemat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON56278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56278.